Rooibos for Health & Longevity - Quick Reference Sheet

Rooibos for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A caffeine-free South African herbal drink with unusual chemistry and thin human evidence. High-volume daily intake lowers markers of fat oxidation and shifts internal antioxidant balance favourably, and supplies plant compounds without caffeine or the iron-blocking effect of ordinary tea. Blood-fat, stress-hormone and heart-muscle findings rest on single small studies; the blood-sugar effect is absent in people studied. (Full Review)

Protocol

Standard intake
6 cups daily
Traditional fermented rooibos, ~2 g leaf per 200 mL freshly boiled water, steeped 5–10 minutes
Split versus single dose
Split dosing
Intake spread across the day with meals rather than a single bolus; time of day is unconstrained
Extract alternative
Standardised capsules, 12 weeks
Green or fermented rooibos extract; carries the interaction and hepatic signals, so brewed tea is the better-characterised route
Time to effect
Oxidative & lipid markers
6 weeks
Measured after six weeks of six cups daily
Heart-muscle mass
12 weeks
Measured after twelve weeks of extract
Enzyme inhibition
Under 1 hour
After a single serving; nothing is perceptible subjectively

Benefits

Contraindications
  • Active liver disease or alanine aminotransferase above 3× the upper limit of normal
  • Prior hepatitis attributed to rooibos or a rooibos-containing herbal blend
  • Solid-organ transplant recipients on tacrolimus (typical target trough 5–15 ng/mL) taking concentrated rooibos extract
  • Hormone-receptor-positive breast or endometrial cancer taking concentrated rooibos extract
Key Interactions
  • CYP3A4 substrates with narrow margins: tacrolimus, ciclosporin, sirolimus, midazolam
  • Statins: atorvastatin, simvastatin
  • Oral glucose-lowering drugs: thiazolidinediones (pioglitazone), sulfonylureas (glibenclamide, gliclazide)
  • Anticoagulants: warfarin
  • Over-the-counter medications: paracetamol (acetaminophen), high-dose non-steroidal anti-inflammatory drugs (ibuprofen, naproxen)
  • Hepatotoxic botanical supplements: concentrated green tea extract, kava, black cohosh, comfrey
  • Supplements with additive effects: blood-pressure-lowering botanicals (hibiscus, hawthorn), glucose-lowering supplements (berberine, cinnamon)
  • Other interventions: no meaningful interaction with exercise, fasting, sauna, or cold exposure

Risk & Side Effects

  • High:
  • Medium:
  • Low: Idiosyncratic Drug-Induced Liver Injury; Raised Liver and Kidney Blood Markers at High Daily Intake; Herb–Drug Interaction via Cytochrome P450 Inhibition; Contaminant and Heavy-Metal Exposure from Plant Material; No Reduction in Kidney-Stone Risk, With an Unfavourable Crystal Shift
  • Speculative: Suppression of Adrenal Steroid Output; Estrogenic Activity; Suppression of Ovarian Cell Function

Monitoring

Marker Target Why
Alanine aminotransferase (ALT) 10–26 U/L (men), 8–22 U/L (women) Detects the idiosyncratic liver injury seen in case reports
Aspartate aminotransferase (AST) 10–26 U/L Confirms and characterises any ALT rise
Gamma-glutamyl transferase (GGT) <20 U/L (men), <15 U/L (women) Most sensitive marker of oxidative hepatic stress
Low-density lipoprotein cholesterol <100 mg/dL (2.6 mmol/L); <70 mg/dL if at high risk The lipid fraction moved most in the human trial
Triglycerides <80 mg/dL (0.9 mmol/L) Fell roughly a quarter in the six-week trial
High-density lipoprotein cholesterol >55 mg/dL (men), >65 mg/dL (women) Rose in the human trial; completes the lipid picture
High-sensitivity C-reactive protein <0.5 mg/L Tracks the inflammatory claim, unproven in humans
Ferritin 50–100 ng/mL Confirms no cost to iron status, unlike ordinary tea
Glycated haemoglobin (HbA1c) 4.8–5.3% Tests the glucose claim, unsupported in human trials
Home blood pressure <120/80 mmHg The enzyme finding predicts a fall no trial has confirmed

Cadence: Baseline before starting high-volume daily rooibos or any concentrated extract; liver panel repeated at 12 weeks; liver and lipid panels every six to twelve months while intake continues. With tacrolimus, warfarin, or a sulfonylurea, a drug-level, clotting-time, or glucose check two weeks after any deliberate change in intake.

Qualitative Assessment

  • Evening calm and time to fall asleep, if displacing caffeinated tea after midday
  • Digestive comfort, the centre of traditional use
  • Daytime energy stability, separating a metabolic shift from a new ritual's placebo effect
  • Right-upper-quadrant discomfort, unusual fatigue, dark urine, or yellowing of the skin